<code id='85CCB1DE88'></code><style id='85CCB1DE88'></style>
    • <acronym id='85CCB1DE88'></acronym>
      <center id='85CCB1DE88'><center id='85CCB1DE88'><tfoot id='85CCB1DE88'></tfoot></center><abbr id='85CCB1DE88'><dir id='85CCB1DE88'><tfoot id='85CCB1DE88'></tfoot><noframes id='85CCB1DE88'>

    • <optgroup id='85CCB1DE88'><strike id='85CCB1DE88'><sup id='85CCB1DE88'></sup></strike><code id='85CCB1DE88'></code></optgroup>
        1. <b id='85CCB1DE88'><label id='85CCB1DE88'><select id='85CCB1DE88'><dt id='85CCB1DE88'><span id='85CCB1DE88'></span></dt></select></label></b><u id='85CCB1DE88'></u>
          <i id='85CCB1DE88'><strike id='85CCB1DE88'><tt id='85CCB1DE88'><pre id='85CCB1DE88'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:knowledge    Page View:52
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In